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C-C chemokine receptor-like 2 (CCRL2) is a non-signaling seven-transmembrane 
domain (7-TMD) receptor related to the atypical chemokine receptor (ACKR) family. 
ACKRs bind chemokines but do not activate G protein-dependent signaling or cell 
functions. ACKRs were shown to regulate immune functions in  vivo by their ability 
to scavenge chemokines from the local environment. This study was performed to 
investigate whether CCRL2 shares two of the main characteristics of ACKRs, namely 
the ability to internalize and scavenge the ligands. Cell membrane analysis of CCRL2-
transfected cells revealed a weak, constitutive, ligand-independent internalization, and 
recycling of CCRL2, with a kinetics that was slower than those observed with ACKR3, 
a prototypic ACKR, or other chemotactic signaling receptors [i.e., chemokine-like 
receptor 1 and C-X-C motif chemokine receptor 2]. Intracellularly, CCRL2 colocalized 
with early endosome antigen 1-positive and Rab5-positive vesicles and with recycling 
compartments mainly characterized by Rab11-positive vesicles. CCRL2-transfected 
cells and activated mouse blood endothelial cells, that endogenously express CCRL2, 
were used to investigate the scavenging ability of CCRL2. These experiments con-
firmed the ability of CCRL2 to bind chemerin, the only recognized ligand, but excluded 
the ability of CCRL2 to perform scavenging. Collectively, these results identify unique 
functional properties for this member of the non-signaling 7-TMD receptor family.
Keywords: chemokine, endocytosis, g protein-coupled receptor, intracellular trafficking, scavenger receptor, 
atypical chemokine receptor, chemerin
inTrODUcTiOn
Chemokines are soluble mediators that regulate immune functions and development, mainly 
through their ability to promote leukocyte trafficking. Chemokines bind seven-transmembrane 
domain (7-TMD) receptors. Chemokine receptors can be divided in two main functional groups: 
the “classical” G protein-coupled signaling receptors (GPCR) and the atypical chemokine receptors 
Abbreviations: CCRL2, C-C chemokine receptor-like 2; ACKR, atypical chemokine receptor; 7-TMD, seven-transmembrane 
domain; GPCR, G protein-coupled receptor; CMKLR1; chemokine-like receptor 1; ACP, acyl carrier protein; CXCR2, C-X-C 
motif chemokine receptor 2; EEA1, early endosome antigen 1; TfR, transferrin receptor; LAMP1, lysosomal-associated 
membrane protein 1; VAMP2, vesicle-associated membrane protein 2; VAMP3, vesicle-associated membrane protein 3; H8, 
helix-VIII; ELISA, enzyme-linked immunosorbent assay.
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(ACKRs) (1). ACKRs do not signal through G proteins, but rather 
they promote ligand internalization and degradation. In some 
cases, ACKRs can also transport the ligand across the cell (2). 
By these mechanisms, ACKRs were shown to regulate chemokine 
availability, shape the chemokine gradient and regulate inflam-
matory responses in vivo (2–5). To date, four 7-TMD receptors 
have been included into the ACKR nomenclature (ACKR1–4). 
An additional 7-TMD receptor, called C-C chemokine receptor 
like 2 (CCRL2), was proposed as the fifth member of the ACKR 
family, pending confirmation of its ability to bind chemokines (1).
Similar to ACKRs, CCRL2 presents in the cytoplasmic 
extension of the third transmembrane helix an altered amino 
acidic sequence (QGYRVFS) in place of the conserved motif 
DRYLAIV, which is required for the triggering of G protein-
mediated responses (1). Although an earlier study reported that 
CCRL2 can signal through MAPK activation and promote cell 
migration (6), a recent report clearly excluded ERK1/2 activa-
tion by CCRL2 (7). Thus, CCRL2 does not trigger classic G 
protein-mediated signaling or mediate cell migration.
Mouse CCRL2 maps within the C-C chemokine receptors gene 
cluster on chromosome 9 and shows high homology with other 
C-C chemokine receptors, sharing 35.8% amino acidic identity 
with C-C motif chemokine receptor 5 (CCR5) and 34.9% with 
C-C motif chemokine receptor 1 (CCR1) (8). Mouse CCRL2 is 
expressed by several leukocytes, including dendritic cells, mac-
rophages, neutrophils, and microglia and is rapidly upregulated 
following stimulation with proinflammatory stimuli, such as LPS 
and TNF-α (9–14). CCRL2 is also expressed by barrier cells, such 
as lymphatic and blood endothelial cells (15, 16) and bronchial 
and intestinal epithelial cells (17, 18). CCRL2 was shown to play 
a role in the regulation of immunity. Indeed, CCRL2-deficient 
mice were protected in a model of IgE-induced anaphylaxis 
(19), in a model of ovalbumin-induced lung hypersensitivity 
(13) and in experimental models of inflammatory arthritis (10). 
On the contrary, CCRL2-deficient mice developed an exacerbated 
inflammatory response when used in a model of experimental 
autoimmune encephalomyelitis (20).
In the past years, it was proposed that CCRL2 may act as the 
receptor for some chemokines, such as CCL2, CCL5, CCL7, 
CCL8, CCL19, and CCL21 (6, 18, 21–23), but these results 
have been questioned by other groups (1). Instead, CCRL2 
was described to bind the non-chemokine chemotactic factor 
chemerin (7, 16, 19, 24). In the currently accepted model, CCRL2 
binds chemerin at the N-terminus and leaves the C-terminus 
accessible for the interaction with cells expressing chemokine-
like receptor 1 (CMKLR1), the functional chemerin receptor. 
Therefore, CCRL2 is proposed to act as a chemerin presenting 
molecule at the surface of barrier cells (19, 25). This model is 
supported by in vitro and in vivo results (15, 16) and assumes that 
CCRL2, differently from all the other ACKRs, does not inter-
nalize, recycle and scavenge the ligand. Nevertheless, human 
CCRL2 was proposed to undergo constitutive internalization of 
a putative ligand (CCL19) in the pre-B cell line Nalm6 and in 
CHO-K1-transfected cells (22, 23). Others did not confirm such 
internalization (7, 16, 19). Thus, the scavenging and recycling 
properties of CCRL2, as well as its biological function, are still a 
matter of debate.
This study was performed to investigate the internalization, 
recycling and scavenging properties of CCRL2, ectopically 
expressed in cell lines or naturally expressed by mouse blood 
endothelial cells. The results here reported formally demonstrate 
that CCRL2, differently from all the other ACKRs, is devoid of 
ligand scavenging properties, and support its proposed function 
as a chemerin anchoring protein on the surface of endothelial 
cells.
MaTerials anD MeThODs
cell culture and Transfection
COS-7 cells and HeLa cells were cultured in DMEM sup-
plemented with 10% fetal bovine serum, 100 U/ml penicillin/
streptomycin, and 2  mM glutamine (all from Gibco by Life 
Technologies, Carlsbad, CA, USA). For transient transfections, 
cells were seeded on glass slides coated with poly-l-lysine in 
order to obtain 90% of confluency on the day of transfection. 
After 24  h, transfection was performed using Lipofectamine 
2000 (ThermoFisher Scientific, Waltham, MA, USA) according 
to manufacturer’s protocol. 1G11 cells are cultures of primary 
mouse blood endothelial cells, used between passage 15–20. 
In culture, 1G11 cells retain the normal expression of CD31, 
ICAM1, VCAM1, and E-selectin up to passage 40 (15, 26). 
When indicated, 1G11 cells were treated either with complete 
medium or with IFNγ (50 ng/ml), TNFα (20 ng/ml), and LPS 
(1 µg/ml) in complete medium overnight. After 18 h, cells were 
rinsed with PBS before performing experiments. For stable 
transfection, cells were transfected with Lipofectamine 2000 as 
previously described. After 24  h, cells were passaged to reach 
a subconfluent concentration. They were maintained and pas-
saged for 2 weeks in the presence of 1 mg/ml Geneticin (Gibco 
by Life Technologies). After 2  weeks, cells were detached and 
sorted for receptor expression as described in Section “Flow 
Cytometry and Cell Sorting.”
Plasmids
C-C chemokine receptor-like 2, CMKLR1, and C-X-C motif 
chemokine receptor 2 (CXCR2) were amplified by PCR, cut 
with EcoRI and XbaI restriction enzymes and cloned into 
pCDNA3.1 plasmids downstream the acyl carrier protein 
(ACP) tag (FWWGLDSLDTVELVMA) or the peptidyl car-
rier protein (PCP) tag (GDSLSWLLRLLN), preceded by the 
leader sequence (MRLCIPQVLLALFLSMLTGPGEGSRRRATQ) 
(27, 28).The following primers were used: mCCRL2 (5′-GAATTC 
GATAACTACACAGTGGCCCCG-3′ and 5′-TCTAGATTAT 
ATTATATCCTG-3′), mCMKLR1 (5′-ATTGAATTCGATGAG 
TACGACGCTTAC-3′ and 5′-ATTTCTAGATCAGAGGGTACT 
GGTCTCC-3′), and mCXCR2 (5′-ATAATAGAATTCGGA 
GAGTTCAAGGTGGATAAGTTC-3′ and 5′-ATAATATCTA 
GATTAGAGGGTAGTAGAGGTGTTTG-3′). ACKR3 was 
cloned downstream the PCP tag as previously described (27).
Non-tagged mCCRL2 and mCXCR2 were cloned in pCDNA3.1 
using the following forward primers: mCCRL2 (5′-ATTGGAATT 
CGAATGGATAACTACACAGTGGC-3′) and mCXCR2 (5′-AC 
CAAGCTTATGGGAGAATTCAAG-3′).
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Two truncated forms of mCCRL2 were cloned downstream 
the tag, the first ending at amino acid 310A before the helix-VIII 
(H8−), the second at amino acid 319F after helix-VIII (H8+). The 
truncated forms were cloned using the following reverse primers: 
H8− (5′-ATTTCTAGACTAGGCCTTCCGGTCAAGAAGC-3′) 
and H8+ (5′-ATTTCTAGACTAGAACAGGCTGCGAAGG 
TATCTCAT-3′).
enzymatic labeling and Quantification  
of receptor internalization
Two short peptides, derived from the PCP and the ACP, act as 
substrates for the phosphopantetheinyl transferases (PPTases) 
Sfp and AcpS. Therefore, PPTases can label receptors tagged with 
either the ACP or PCP tag, in the presence of CoA functional-
ized with a fluorophore, as described (29, 30). Cells were seeded 
on glass slides and transiently transfected with the plasmids 
described above. After 24 h, receptors were labeled using either 
the enzyme AcpS (ACP tag) or Sfp (both ACP and PCP tags) 
that transfer the fluorophore from the CoA to the tag. Cells 
were incubated at 17°C during the reaction, to prevent receptor 
endocytosis, and then washed thoroughly with PBS at room 
temperature. Next, cells were incubated at 37°C in complete 
medium in the presence of the different stimuli for the indicated 
times. CoA functionalized with 594 fluorophore (CoA-594) was 
prepared as described (27, 31); Sfp and AcpS were from New 
England BioLabs. When required, before fixation the membrane 
was marked by incubating cells with Wheat Germ Agglutinin 
(WGA), Alexa Fluor® 488 conjugate (Invitrogen, ThermoFisher 
Scientific, Waltham, MA, USA), diluted 1:150 in HBSS buffer, 
at 17°C for 10 min. Fluorescence microscopy of living or fixed 
cells was performed with Zeiss Observer.Z1 microscope using a 
100× (1.4 numerical aperture) oil immersion lens and Apotome2 
for optical sectioning. Images were acquired using AxioVision 
software. Images were analyzed using ImageJ 1.48 (National 
Institutes of Health; http://rsb.info.nih.gov/ij/) to quantify 
receptor internalization. Two gates were designed for each cell 
with the help of the WGA staining: one including the membrane 
and one excluding the membrane. After converting images to 
8-bit, a threshold of fluorescence was defined and the number of 
pixels over the threshold was counted inside the gates. Receptor 
internalization is expressed as ratio between internal and total 
fluorescence measured for each single cell.
immunofluorescence
Cells were enzymatically labeled, fixed in 2% paraformaldehyde, 
7% sucrose, in PBS. Free aldehydic groups from paraformalde-
hyde were covered incubating with 50 mM NH4Cl for 10 min. 
Buffer containing 0.25% Saponin, 5% normal goat serum, and 
2% serum bovine albumine in PBS was used for permeabiliza-
tion and blocking; incubation with antibodies was performed in 
the presence of 0.25% Saponin. The following primary anti-
bodies were used: mouse antiearly endosome antigen 1 (anti-
EEA1) 1:100 (610456, BD Biosciences, San Jose, CA, USA); rabbit 
antilysosomal-associated membrane protein 1 (anti-LAMP1) 
1:500 (ab24170; abcam, Cambridge, UK); rabbit anti-Rab4 1:100 
(sc-312, Santa Cruz Biotechnology, Santa Cruz, CA, USA); rabbit 
anti-Rab5 1:100 (sc-28570, Santa Cruz Biotechnology); rabbit 
anti-Rab7 1:100 (sc-10767, Santa Cruz Biotechnology); 
rabbit anti-Rab11 10  µg/ml (71-5300, Invitrogen); mouse 
antivesicle-associated membrane protein 2 (anti-VAMP2) 
1:500 (Synaptic Systems, Gottingen, Germany); rabbit anti-
VAMP3 1:200 (ThermoFisher Scientific); rabbit anti-Syntaxin-6 
1:100 (Synaptic Systems); and mouse antitransferrin receptor 
(anti-TfR) 1:200 (Invitrogen). The secondary antibodies used 
were: goat anti-Mouse Alexa Fluor® 405 conjugate 1:250 
(Invitrogen); goat anti-Rabbit DyLight 405 conjugate 1:500 
(ThermoFisher Scientific). Immunofluorescence microscopy 
was performed as described before.
Flow cytometry and cell sorting
Hela cells transiently transfected with the truncated forms of 
CCRL2 were detached and labeled using AcpS in suspension at 
17°C. Cells were then washed and analyzed by flow cytometry. 
Alternatively, CCRL2 was labeled using anti-mCCRL2-PE (clone 
BZ2E3, BD Pharmigen, BD Biosciences). CMKLR1 was labeled 
using anti-mCMKLR1-PE (Clone # 477806, R&D Systems, 
Minneapolis, MN, USA). Flow cytometry analysis was performed 
using MACSQuant® Analyzer Miltenyi, files were plotted using 
FlowJo software (TreeStar Inc.).
For sorting, cells were labeled with appropriate antibodies, 
resuspended in PBS containing 0.5% BSA and 5  mM EDTA, 
filtered through a cell strainer and sorted with FACSAria III cell 
sorter (BD).
enzyme-linked immunosorbent  
assay (elisa)
Cells were incubated in DMEM, containing 4 mM HEPES and 
1% BSA, in the presence or in the absence of 1 nM of chemerin 
(R&D) or CCL19 (Peprotech, Rocky Hill, NJ, USA) for the indi-
cated times. Where indicated, cells were preincubated with 80 µm 
Dynasore (dynamin inhibitor, Sigma, St. Louis, MO, USA). After 
incubation, residual ligand in the supernatant was quantified by 
ELISA (DY2324 and DY361, R&D).
To evaluate chemerin into the cells, cells were incubated as 
previously described, in the absence or in the presence of 1 nM 
chemerin at 37°C for 2 h. Then plates were put in ice and rinsed with 
PBS. Cells were washed with different buffers for 5 min at room 
temperature: PBS, acidic buffer [150 mM NaCl, 100 mM glycine, 
pH = 3, in water (32)], or acidic followed by high salt buffer (2 M 
NaCl in water). After rinsing with PBS, cells were lysed for 30 min 
in ice (1% Triton X-100, 5 mM EDTA, in PBS), then centrifuged 
(16,000g) at 4°C for 15 min. Internalized chemerin was evaluated 
by ELISA from supernatants obtained after centrifugation. The 
quantity of chemerin was normalized over total protein content, 
quantified using Bradford reagent (Biorad, Hercules, CA, USA).
gene expression
Cells were lysed using TRIzol (Life Technologies) and total 
RNA was extracted following manufacturer’s protocol. cDNA 
was prepared from 500 ng of total RNA using M-MLV Reverse 
Transcriptase (ThermoFisher Scientific). mRNA expression was 
determined by quantitative PCR using SYBR Green (BioRad). PCR 
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reactions were performed using StepOnePlus Real-Time PCR 
system (Applied Biotechnologies by ThermoFisher). Threshold 
cycle values (Ct) were determined and relative mRNA expres-
sion was analyzed by the comparative ΔCt method. Data 
were normalized to the mRNA expression of RPL32 (murine 
samples) or GAPDH (human samples). The following primers 
were used: mCCRL2 (5′-TGTGTTTCCTGCTTCCCCTG-3′ 
and 5′-CGAGGAGTGGAGTCCGACAA-3′), mCMKLR1 
(5′-CCATGTGCAAGATCAGCAAC-3′ and 5′-GCAGGAA-
GACGCTGGTGTA-3′), mRPL32 (5′-GCTGCCATCTGTTT-
TACGG-3′ and 5′-TGACTGGTGCCTGATGAACT-3′), and 
hGAPDH (5′-AGCCACATCGCTCAGACA-3′ and 5′-GCCCAAT 
ACGACCAAATCC-3′).
statistical analysis
When not specified, graphics represent mean values  ±  SEM. 
Statistical significance between the experimental groups was 
determined by using one- or two-way ANOVA with Bonferroni 
posttest, or unpaired t-test (GraphPad Prism; GraphPad Software, 
La Jolla, CA, USA). p-Values of <0.05 were considered significant.
resUlTs
ccrl2 Displays a slow, constitutive, 
ligand-independent internalization
To study the intracellular trafficking, acyl carrier protein (ACP)-
tagged CCRL2 was expressed in HeLa cells and receptors were 
enzymatically labeled using a fluorescent dye. Living cells are 
impermeable to the dye, therefore this reaction, when performed 
before fixation, labels only the tagged proteins present at the cell 
surface. Indeed, immediately after labeling the fluorescence sig-
nal was detected only at the plasma membrane level (Figure 1A). 
After a few minutes of incubation at 37°C, fluorescent vesicles 
started to be detectable also in the cytoplasm and progressively 
accumulated in the perinuclear region (Figure 1A). The degree 
of internalized fluorescence increased over time reaching about 
20% of total fluorescence after 60 min incubation (Figure 1A). 
Since ACKRs are characterized by rapid constitutive inter-
nalization (33–35), the kinetics of CCRL2 internalization was 
compared to that of ACKR3, a receptor belonging to the ACKR 
family (34), and to that of two chemotactic receptors, namely 
CXCR2 and CMKLR1. Tagged CCRL2, CXCR2, CMKLR1, 
and ACKR3 were expressed in HeLa cells and enzymatically 
labeled. All the receptors showed comparable levels of baseline 
internalization, with the only exception of ACKR3. Indeed, 
intracellular ACKR3-positive vesicles were clearly detectable 
at time zero, indicating that receptor internalization occurred 
even during the washing steps performed at room temperature 
(Figures  1B,C). The kinetics of CCRL2 internalization was 
similar to those of CXCR2 and CMKLR1, although the degree 
of internalization of CCRL2 was lower (Figure 1C). A similar 
pattern of internalization was observed when CCRL2 was 
expressed in COS-7 cells (data not shown).
Since 7-TMD receptor internalization is usually increased 
upon ligand binding interaction (36), the effect of known 
or putative ligands on CCRL2 and CMKLR1 internalization 
was investigated. The addition of chemerin or CCL19 did not 
modify the internalization kinetics of CCRL2 (Figure 1D, upper 
panel). Instead, CMKLR1 internalization was rapidly increased 
upon chemerin stimulation (Figure  1D, lower panel). A panel 
of chemokines was tested to further explore a possible ligand-
induced internalization of CCRL2. Of 29 chemokines tested 
(Table 1), none of them enhanced the degree of CCRL2 inter-
nalization (not shown).
internalized ccrl2 Follows the slow 
recycling Pathway
Time lapse imaging of membrane ACP-CCRL2-labeled cells 
showed that CCRL2-positive vesicles moved from the cell 
membrane toward the cytoplasm and back to the cell membrane 
(Figure 2; Video S1 in Supplementary Material). This observa-
tion suggested that, upon internalization, CCRL2 could recycle 
to the cell membrane. To prove this hypothesis, the colocalization 
of CCRL2 with specific markers of distinct intracellular com-
partments was investigated by immunofluorescence. CCRL2 
was found to colocalize with Rab5- and EEA1-positive early 
endosomes (Figure  3). From early endosomes, receptors can 
recycle to the plasma membrane either via Rab4+ vesicles (rapid 
recycling pathway) or alternatively via Rab11+ vesicles (slow recy-
cling pathway) (37, 38). CCRL2 was mostly observed colocalized 
with Rab11+ and only occasionally with Rab4+ vesicles. Indeed, 
CCRL2 colocalized also with the TfR, a reference receptor for 
recycling pathways (Figure  3) (39). Of note, a significant por-
tion of the internalized receptors was not associated with any of 
the endosomal markers. This is probably due to technical issues 
dealing with the different intensity of florescent staining of tagged 
receptors vs. moAb-labeled markers and with the flat shape of 
COS-7 cells that brings in close contact the upper and lower por-
tion of the cell membrane. From EEA1-positive vesicles recep-
tors can either recycle or be directed to lysosomal degradation. 
However, the lack of colocalization with Rab7 (a late endosome 
marker) or LAMP1 (a lysosome marker) argued against the possi-
ble localization of CCRL2 in lysosomal compartments. Similarly, 
the absence of colocalization with VAMP2 and VAMP3 and sin-
taxin-6 immunostaining excluded the association of CCRL2 with 
the Golgi compartment (Figure S1 in Supplementary Material).
ccrl2 c-Terminus is Dispensable  
for receptor internalization
To investigate the mechanisms involved in CCRL2 inter-
nalization, two C-terminus truncated forms of the receptor 
were expressed in HeLa cells. One form, named CCRL2-H8-, is 
truncated after 310 A and lacks the entire C-terminus. The second 
form of the receptor, named CCRL2-H8+, is truncated after the 
amino acid 319 F and includes a structure called helix-VIII (H8). 
H8 is an alpha-helical structure present in class-A GPCRs and 
related to several molecular events, such as receptor expression, 
internalization, G protein coupling, regulation of activation and 
β-arrestin recruitment (40, 41). Figure  4B shows that, despite 
similar mRNA expression levels (Figure  4A), cell membrane 
expression of CCRL2-H8− was reduced when compared to 
CCRL2-H8+ or the full-length CCRL2. These results suggest that 
the presence of H8 is required for the trafficking of CCRL2 from 
FigUre 1 | C-C chemokine receptor-like 2 (CCRL2) internalization is ligand independent. HeLa cells were transfected with acyl carrier protein (ACP)-CCRL2, 
ACP chemokine like receptor 1 (CMKLR1), peptidyl carrier protein-C-X-C motif chemokine receptor 2 (PCP-CXCR2), or PCP-atypical chemokine receptor 3 
(ACKR3) expression vectors and receptors were labeled. Cells were then incubated at 37°C in serum-free medium for the indicated times and fixed. Images 
were taken using 100× magnification and analyzed using ImageJ 1.48 (NIH). (a) Representative images (above) and quantification (below) of ACP-CCRL2 
internalization after 0, 15, 30, 60 min of incubation. Internalization is expressed as the ratio between internal and total fluorescence, calculated on each single 
cell. One experiment representative of two is shown; each point represents the average value ± SEM calculated on 19–32 cells. (B) Representative images of 
labeled ACP-CCRL2, ACP-CMKLR1, PCP-CXCR2, and PCP-ACKR3, at 0 and 60 min incubation. Scale bars: 10 µm. (c) ACP-CCRL2, ACP-CMKLR1, 
PCP-CXCR2, and PCP-ACKR3 internalization, calculated as in (a). One experiment representative of two is shown; each point represents the average 
value ± SEM calculated on 20–50 cells. **p < 0.01 and ***p < 0.001 by two-way ANOVA. (D) (Above) After labeling of ACP-CCRL2, cells were incubated in 
the presence of 100 nM CCL19 or 100 nM chemerin for the indicated times. Internalization was measured as described before; analysis by two-way ANOVA; 
ns, not significant (CCRL2 vs. CCRL2 + chem and CCRL2 + CCL19). (Below) After labeling of ACP-CMKLR1, cells were incubated in the presence or in the 
absence of 100 nM chemerin for the indicated times; internalization was measured as described before. ***p < 0.001 by two-way ANOVA (CMKLR1 vs. 
CMKLR1 + chem). In both the graphs, one representative of two independent experiments is shown, each point represents the average values ± SEM 
calculated on 20–50 cells.
TaBle 1 | Chemokines that do not induce CCRL2 internalization.
cc CCL2 CCL3 CCL4 CCL5 CCL7 CCL8 CCL13 CCL17
CCL18 CCL20 CCL22 CCL23 CCL24 CCL25 CCL26
cXc CXCL1 CXCL2 CXCL4 CXCL5 CXCL6 CXCL7 CXCL8 CXCL10
CXCL11 CXCL12 CXCL13 CXCL14
cX3c CX3CL1
Xcl XCL1
Hela cells transfected with ACP-CCRL2 and enzymatically labeled were incubated with 100 nM of the chemokines listed subsequently.
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FigUre 2 | Time-lapse microscopy analysis of C-C chemokine receptor-like 
2 (CCRL2)-positive vesicles. COS-7 cells expressing acyl carrier protein 
(ACP)-CCRL2 were enzymatically labeled. After labeling, cells were placed 
under the microscope at 37°C, in the presence of 5% CO2, and observed by 
time-lapse microscopy every 5 s. Pink line, endocytosing vesicle; yellow line, 
exocytosing vesicle.
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intracellular compartments to the cell membrane after its transla-
tion. Conversely, H8 seems to be dispensable for internalization, 
since the absence of H8 did not abrogate CCRL2 localization into 
intracellular vesicles (Figure 4C).
ccrl2-Transfected cells internalize 
chemerin
C-C chemokine receptor-like 2 scavenging properties were 
analyzed in the past by several investigators yielding contrasting 
results (16, 23). To clarify this issue, HeLa cells stably expressing 
non-tagged CCRL2 were cultured in the presence of chemerin or 
CCL19. As shown in Figure 5A, a time-dependent decrease of 
chemerin, but not of CCL19, concentration was detected in the 
supernatant of CCRL2-expressing cells. As expected, no changes 
in chemerin or CCL19 concentrations were observed in the 
supernatants of non-transfected HeLa cells.
To elucidate whether the decrease in chemerin concentration 
in cell supernatants was due to the binding of the protein to 
the cell membrane and/or to CCRL2-mediated endocytosis, 
experiments were performed in the presence of dynasore, a 
dynamin inhibitor able to block endocytosis (42). Figure  5B 
shows that dynasore inhibited about 50% of chemerin consump-
tion by CCRL2-transfected cells. These results suggest that, at 
least at the analyzed time point, only a fraction of chemerin is 
actively endocytosed while the rest is bound to the cell surface. 
Chemerin was quantified into the cell lysates obtained from 
chemerin-treated cells. Before lysis, cells were washed with 
either PBS alone, an acidic buffer, or an acidic buffer followed 
by a high salt buffer. Figure 5C shows that about 50% of cell-
associated chemerin (found after incubation in PBS alone) 
could be removed from CCRL2-expressing cells by acidic and 
high salt washes. As expected, no chemerin was found associ-
ated with cells that do not express CCRL2. These results together 
with the data obtained in the presence of dynasore support the 
hypothesis that chemerin interacts with membrane CCRL2 and 
becomes internalized.
To further confirm these observations, HeLa cells stably 
expressing CMKLR1 were cultured in the presence of chemerin 
and its decrease from cell supernatants was analyzed. CMKLR1-
positive cells removed chemerin from the supernatants in a 
time-dependent way (Figure 5D). Of note, chemerin consump-
tion by CMKLR1-expressing cells was higher compared to the 
one of CCRL2-expressing cells (Figure 5D).
ccrl2 Does not act as a scavenger 
receptor When endogenously expressed 
by endothelial cells
To investigate the scavenging properties of CCRL2 in a more 
physiological cell system, mouse blood endothelial cells (1G11) 
were used (15). In resting conditions, 1G11 cells express 
CMKLR1 but only very low levels of CCRL2 mRNAs. When 
1G11 cells are stimulated with proinflammatory cytokines, the 
two receptors are modulated in an opposite manner with the 
upregulation of CCRL2 and the downregulation of CMKLR1 
(Figure 6A). Of note, CCRL2 expression in cytokine-stimulated 
1G11 cells is much lower than what observed in CCRL2-
transfected HeLa cells, being about 40-fold lower (mRNA) and 
10-fold lower (membrane protein), respectively (Figure  6B). 
When resting 1G11 cells were cultured in the presence of 
chemerin, a time-dependent reduction of chemerin concentra-
tion was observed in the cell supernatant. Conversely, culturing 
of chemerin-treated cytokine-activated 1G11 cells did not cause 
any change in chemerin levels (Figure 6C). Since resting 1G11 
cells express high levels of CMKLR1, but also very low levels 
of CCRL2, the role of CMKLR1 in chemerin consumption was 
investigated. Figure 6D shows that treatment of 1G11 resting 
cells with a CMKLR1 selective antagonist (43) completely 
abrogated chemerin decrease in the supernatant. Conversely, 
the CMKLR1 antagonist did not show any effect when added to 
stimulated cells (Figure 6D).
DiscUssiOn
This study was performed to investigate the internalization and 
scavenging properties of CCRL2, a 7-TMD receptor that shares 
structural similarities with the members of the ACKR family 
(44). Similar to ACKRs, CCRL2 does not activate G protein-
dependent signaling or chemotaxis. However, the ability of 
CCRL2 to internalize and degrade its ligand still represents an 
open and controversial question (7, 23). Since it is possible that 
the discrepancies among different studies are due to technical 
artifacts, possibly related to the quality of commercially avail-
able moAbs, we decided to reevaluate CCRL2 internalization 
FigUre 3 | C-C chemokine receptor-like 2 (CCRL2)-positive vesicles colocalize with markers of the slow recycling pathway. COS-7 cells expressing acyl carrier 
protein (ACP)-CCRL2 were enzymatically labeled. After labeling, cells were incubated at 37°C for 20 min, fixed, permeabilized and mounted after staining for the 
indicated markers. Images were taken at 100× magnification. Labeled CCRL2 and the fluorescent intracellular markers are shown in the first and the second 
columns, respectively. The third column represents the merging of CCRL2 (red) and marker (green) fluorescences. Inserts represent magnifications of the boxed 
areas. Scale bars: 10 µm.
7
Mazzotti et al. CCRL2 Is Not a Scavenger Receptor
Frontiers in Immunology | www.frontiersin.org October 2017 | Volume 8 | Article 1233
properties using a more direct approach that has been already 
used to successfully investigate intracellular trafficking of other 
7-TMD receptors (27). For this purpose, CCRL2 was tagged at 
its extracellular N-terminus with a small peptide that can be 
covalently bound to a fluorophore by a highly specific enzymatic 
reaction (28). By using this technique, receptor labeling is 
chemically stable, is not sensitive to acidic pH and marks only 
receptors expressed at the cell membrane in living cells.
By this labeling approach, ectopically expressed CCRL2 was 
observed to undergo constitutive internalization and recycling 
to the plasma membrane following the slow recycling pathway. 
The analysis of CCRL2 internalization suggested that CCRL2 
behaves differently from both ACKRs and classical chemotactic 
receptors. Indeed, the degree of CCRL2 internalization was 
lower than that observed for CXCR2 and CMKLR1, two signal-
ing chemotactic receptors which, in turn, showed a very modest 
FigUre 5 | Chemerin, but not CCL19, is internalized by C-C chemokine 
receptor-like 2 (CCRL2)-transfected HeLa cells. (a) Hela cells stably 
expressing CCRL2 (CCRL2) or control cells (CTR) were incubated with 
1 nM chemerin or 1 nM CCL19. At the indicated times, supernatants were 
collected and ligand concentration was assessed by enzyme-linked 
immunosorbent assay (ELISA). The mean values of three independent 
experiments are shown; the values for each ligand were normalized over 
the value of the respective control at 1 h of incubation. ***p < 0.001 
(CCRL2 + chemerin vs. CTR + chemerin) by two-way ANOVA.  
(B) Hela cells stably expressing CCRL2 (CCRL2) or control cells (CTR) 
were pre-incubated with 80 µM Dynasore or 0.1% DMSO for 1 h, then 
chemerin was added to the final concentration of 1 nM. After 1 h 
incubation, supernatants were collected and chemerin concentration was 
assessed by ELISA. Chemerin concentration was normalized over the one 
of DMSO-treated control cells. The mean values of three independent 
experiments are shown. *p < 0.05; **p < 0.01; ***p < 0.001, by one-way 
ANOVA followed by Bonferroni’s multiple comparison test. (c) Hela cells 
stably expressing CCRL2 (CCRL2) or control cells (CTR) were incubated 
for 2 h in the absence (no chemerin) or in the presence of 1 nM chemerin. 
Cells were then washed with PBS (PBS), acidic buffer (pH3) or with acidic 
buffer followed by high salt buffer (pH3 + NaCl), for 5 min. Then, cells were 
lysed and whole cell lysates were analyzed by ELISA for chemerin 
concentration. The mean values of three independent experiments are 
shown. ***p < 0.001, by one-way ANOVA followed by Dunnett’s multiple 
comparison test. (D) Chemokine-like receptor 1 (CMKLR1)- or CCRL2-
expessing HeLa cells or control cells were incubated with 1 nM chemerin 
for the indicated times. Supernatants were collected and chemerin 
concentration was assessed by ELISA. The values were normalized over 
no cells, at 1 h of incubation; the mean values of three independent 
experiments are shown. *p < 0.05 (CMKLR1- vs. CCRL2-expressing cells) 
by two-way ANOVA; CTR, control HeLa cells; CCRL2, HeLa cells stably 
expressing mCCRL2; CMKLR1, HeLa cells stably expressing mCMKLR1; 
no cells, supernatant incubated in the absence of cells; Dyn, Dynasore; ns, 
not significant.
FigUre 4 | C-C chemokine receptor-like 2 (CCRL2) C-terminus is 
dispensable for receptor internalization. HeLa cells were transfected with a 
acyl carrier protein (ACP)-CCRL2, or with the truncated forms of ACP-CCRL2 
(H8+ or H8−). (a) Total RNA was extracted 24 h after transfection and CCRL2 
mRNA expression quantified by qPCR. 2−ΔCT values are reported as average 
values of two independent experiments performed in triplicate. (B) 24 h after 
transfection, cell membrane receptors were fluorescently labeled and cells 
were analyzed by flow cytometry. Data were analyzed using the FlowJo 
software. The mean values of three independent experiments are shown; 
median fluorescence intensity of untransfected cells was subtracted and 
values were normalized over the mean fluorescence intensity of cells 
expressing non-truncated CCRL2 set at 100. (c) 24 h after transfection,  
cell membrane ACP-CCRL2 were fluorescently labeled. Cells were then 
placed at 37°C for 20 min and then fixed. Images were taken using  
100× magnification. *p < 0.05 (H8− vs. CCRL2) by Student’s t-test.
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degree of internalization when compared to ACKR3, a well 
characterized scavenger receptor (1). In addition, the kinetics 
of CCRL2 internalization was not modified by treatment with 
chemerin or by several other chemokines. On the contrary, the 
internalization of CMKLR1, the chemerin functional receptor, 
was significantly increased following chemerin stimulation. 
Noteworthy, similar patterns of internalization were observed 
using two different recipient cells (HeLa and COS-7 cells), 
indicating that the cellular context in which the receptor is 
expressed does not modify CCRL2 trafficking. The finding that 
the C-terminus and the putative H8 are dispensable for CCRL2 
internalization further differentiates CCRL2 from the ACKR 
family members (e.g., ACKR3) (27). H8 is a sequence predicted 
to interact with arrestins (40), a family of proteins that play an 
important role in clathrin-driven internalization (45). Therefore, 
the finding that H8 is dispensable for CCRL2 internalization is 
consistent with a recent report, showing that CCRL2 does not 
associate with β-arrestin1 and 2 (7). Although it should be noted 
that β-arrestin-independent internalization was reported to 
occur also with some chemokine receptors, such as CXCR3 (46).
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and activated endothelial cells is likely to reside in the 40-fold 
higher expression of CCRL2 in transfected cells compared to 
the physiological expression observed in activated endothelial 
cells. Ultimately, these data fully support the proposed function 
of CCRL2 as a membrane-anchoring protein for the presenta-
tion of chemerin to CMKLR1-expressing cells (16, 19).
In conclusion, this study demonstrates that CCRL2 does 
not possess two of the hallmarks of ACKRs: first, the ability to 
undergo rapid, constitutive, membrane internalization; second, 
the ability to scavenge the ligand from the cell supernatant. These 
aspects clearly differentiate CCRL2 from the other members of 
the ACKR family. By sequence homology with chemokine 
receptors, CCRL2 has always been cited as a receptor. However, 
a hallmark and prerequisite for defining a molecule as a recep-
tor is the ability to trigger intracellular signaling. Thus, without 
evidence of such a signaling, at the moment, CCRL2 should be 
classified simply as a chemerin binding protein (48). Nonetheless, 
the data obtained using CCRL2 KO mice clearly support a crucial 
role of CCRL2 in the regulation of the immune response in vivo 
(10, 13, 15, 19, 20). Further studies are required to fully elucidate 
the mechanisms by which CCRL2 regulates immune functions.
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FigUre 6 | C-C chemokine receptor-like 2 (CCRL2) does not behave as a scavenger receptor when endogenously expressed by endothelial cells. 1G11 mouse 
endothelial cells were incubated overnight with medium (DMEM) or with IFNγ (50 ng/ml), TNFα (20 ng/ml), and LPS (1 µg/ml) (mix). (a) CCRL2 (above) or 
chemokine-like receptor 1 (CMKLR1) (below) mRNA expression in 1G11 mouse endothelial cells, at 18 h after treatment. 2−ΔCT values were normalized over mix  
(for CCRL2 expression) or over DMEM (for CMKLR1 expression); the average values of four independent experiments are shown. (B) CCRL2 protein (white) and 
mRNA (black) expression in 1G11 cells, in control HeLa cells or in HeLa cells stably expressing CCRL2, evaluated by flow cytometry and qPCR, respectively. For 
protein expression, median values of fluorescence intensities of labeled cells were normalized over median of fluorescence intensities of unlabeled cells. For mRNA 
expression, the number of copies of CCRL2 is reported; quantification was performed using a plasmid standard curve. The mean values of four independent 
experiments are shown. (c) 18 h after incubation in the presence or in the absence of the mix of cytokines (mix), cells were incubated with 1 nM chemerin. At the 
indicated times, supernatants were collected and chemerin concentration was assessed by ELISA. Chemerin concentration was normalized over the one of no cells 
at 1 h; the mean values of three independent experiments are shown. (D) 1G11 Cells were pre-incubated with 0.1% DMSO or 10 µM mCMKLR1 antagonist for 
10 min, then chemerin was added to the final concentration of 0.1 nM. After 1 h incubation, supernatants were collected and chemerin concentration was assessed 
by ELISA. Chemerin concentration in each sample was normalized over the concentration of chemerin incubated in the absence of cells (not shown in the graph); 
the mean values of three independent experiments are shown. ***p < 0.0001 by Student’s t-test; *p < 0.05 (mix vs. DMEM) and #p < 0.05 (CCRL2 vs. CTR),  
by Student’s t-test; **p < 0.01 and ##p < 0.001 by two-way ANOVA; ns, not significant. CTR, control HeLa; CCRL2, HeLa stably expressing mCCRL2; no cells, 
supernatant incubated in the absence of cells; mix, IFNγ + TNFα + LPS.
Since one of the ACKR hallmarks is the ability to scavenge 
chemokines as a way to control inflammation (3), it was of inter-
est to investigate whether the slow rate of CCRL2 internalization 
is associated with ligand scavenging. Our experiments dem-
onstrate that CCRL2 promotes a time-dependent decrease of 
chemerin concentration in the supernatant of transfected cells. 
However, in the same experimental conditions, ectopic expres-
sion of CMKLR1 was associated with even a higher ability to 
remove chemerin from the supernatant. It is worth to consider 
that CMKLR1 is a GPCR that, similar to other chemotactic recep-
tors, activates signaling and internalizes after ligand binding (7). 
This type of ligand internalization cannot be compared to the 
ligand scavenging ability that characterizes ACKRs. Therefore, 
chemerin endocytosis mediated by CMKLR1 and CCRL2 
when ectopically expressed in transfected cells is an effect related 
to the biological behavior shared by all chemotactic receptors 
(47) and does not reflect the specialized scavenging functions 
displayed by ACKRs.
To further investigate CCRL2 scavenging properties, a more 
physiological cell system was used, namely primary cultures 
of mouse endothelial cells (15, 26). Resting 1G11 endothelial 
cells induced a CMKLR1-dependent decrease of chemerin 
concentration in the cell supernatant and this effect was fully 
blocked by a CMKLR1 antagonist. On the contrary, no change 
in chemerin concentration was observed in the presence of 
activated endothelial cells. Activated 1G11 cells are known 
to upregulate CCRL2 and simultaneously downregulate 
CMKLR1 expression. The apparent discrepancy between the 
results obtained with CCRL2-stably transfected HeLa cells 
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